Skip to main content
Smart Investors Daily
SL

NASDAQ · SLXN

Silexion Therapeutics Ltd.

Healthcare · Biotechnology

$0.32

Down-$0.08 (-19.63%)

Updated Sep 24, 2026, 8:48 AM

SID Score

2.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
1.69M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.23 – $5.45
Volume
8.32M
Avg. volume
205.66K

Price performance

SLXN price history

1M range · 20 trading sessions · Daily adjusted prices

SLXN closed at $0.32 after 20 trading sessions, down 11.16% for the selected period.

Last close
$0.32
Period change
-11.16%
Period low
$0.32
Period high
$0.54
Daily close
View OHLC price history
SLXN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 23, 2026$0.3386$0.3824$0.30$0.31538.32M
Sep 22, 2026$0.4921$0.50$0.3282$0.392332.53M
Sep 21, 2026$0.42$0.6303$0.4149$0.544120.13M
Sep 18, 2026$0.3855$0.4492$0.384$0.435527.81M
Sep 17, 2026$0.366$0.39$0.3477$0.388.52M
Sep 16, 2026$0.34$0.3495$0.3222$0.342.48M
Sep 15, 2026$0.335$0.3546$0.3241$0.3436.97M
Sep 14, 2026$0.3479$0.40$0.344$0.3854890.63K
Sep 11, 2026$0.36$0.3878$0.3393$0.35732.58M
Sep 10, 2026$0.4152$0.4871$0.3849$0.4225118.95M
Sep 9, 2026$0.3452$0.3557$0.335$0.349567.4K
Sep 8, 2026$0.364$0.364$0.3353$0.3449189.02K
Sep 4, 2026$0.372$0.38$0.3516$0.3518204.05K
Sep 3, 2026$0.36$0.3743$0.3515$0.3516130.98K
Sep 2, 2026$0.38$0.3899$0.3502$0.3512184.1K
Sep 1, 2026$0.36$0.39$0.36$0.3701179.94K
Aug 31, 2026$0.369$0.3755$0.36$0.3697155.69K
Aug 28, 2026$0.37$0.3759$0.353$0.362877.19K
Aug 27, 2026$0.3504$0.38$0.3501$0.3602286.23K
Aug 26, 2026$0.374$0.374$0.3506$0.3549228.41K

Latest SLXN news

The latest Smart Investors Daily articles mentioning SLXN.

SLXN research

Overview

Company profile and research snapshot.

Company profile

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
SLXN recent ratings
DateFirmRatingTarget
Dec 15, 2025Litchfield HillsBuy
Mar 20, 2025Maxim GroupBuy
Nov 1, 2024Maxim GroupBuy
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Sep 11, 2026

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap stands at

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.